AI Article Synopsis
- Vanishing bile duct syndrome (VBDS) is an acquired liver disease marked by the destruction of intrahepatic bile ducts, often linked to underlying conditions like Hodgkin's lymphoma.
- The case presented involves a 69-year-old woman with symptoms including jaundice and fatigue, leading to a diagnosis of Hodgkin's lymphoma after further medical imaging.
- Despite treatments such as steroids and chemotherapy, the patient ultimately passed away, underscoring the need for increased awareness and consideration of VBDS in diagnosing painless jaundice associated with cholestatic liver dysfunction.
Article Abstract
Vanishing bile duct syndrome (VBDS) is a clinicopathological term coined to describe an acquired liver disease characterised by progressive destruction and disappearance of intrahepatic biliary ducts. We report the case of a 69-year-old female who presented with painless jaundice, fatigue, and weight loss. Initial blood workup revealed hyperbilirubinemia, transaminitis, elevated alkaline phosphatase, and a raised international normalised ratio. Para-aortic lymphadenopathy on computed tomography of the abdomen was biopsied to confirm the diagnosis of Hodgkin's lymphoma. Vanishing bile duct syndrome is a paraneoplastic phenomenon of Hodgkin's lymphoma, a recognised cause of cholestatic jaundice, and our patient's liver biopsy was diagnostic of the same. Despite treatment with steroids, ursodeoxycholic acid, and chemotherapy, our patient passed away. This case report aims to highlight VBDS as a differential diagnosis for painless jaundice in the context of cholestatic liver dysfunction. We believe reporting such cases irrespective of their outcome will help raise awareness of VBDS among clinicians, thus bettering the rate at which it is diagnosed and treated, thereby improving patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11453172 | PMC |
| http://dx.doi.org/10.7759/cureus.68724 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Idiopathic Vanishing Bile Duct Syndrome in a Young Female: A Case Report.
Korean J Gastroenterol
December 2024
Department of Internal Medicine, Pusan National University College of Medicine, Yangsan, Korea.
Vanishing bile duct syndrome (VBDS) is characterized by the progressive loss and destruction of the intrahepatic bile ducts, leading to bile stasis and associated symptoms such as jaundice. This condition is commonly associated with drug side effects, infections, neoplasms, and autoimmune diseases, but the precise mechanism of its development is unclear. Although VBDS can be diagnosed based on the patient's symptoms and disease progression, a liver biopsy is essential for confirmation, and the prognosis can vary significantly.
View Article and Find Full Text PDFDrug-induced liver injury related to avacopan therapy.
Rheumatology (Oxford)
December 2024
Department of Rheumatology, Tohoku University Hospital, Sendai, Miyagi, Japan.
Objectives: The efficacy of avacopan as remission induction therapy for Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (AAV) is well-established. However, concerns regarding liver injury post-avacopan treatment remain, especially in Japan. Therefore, this study aimed to investigate drug-induced liver injury (DILI) associated with avacopan treatment.
View Article and Find Full Text PDFPexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Breast Cancer Res Treat
December 2024
University of California San Francisco, Box 1710, San Francisco, CA, 94143, USA.
Purpose: We investigated the small-molecule receptor tyrosine kinase-inhibitor of colony-stimulating factor-1 receptor pexidartinib in the stage II/III breast cancer in the I-SPY2 platform trial.
Methods: I-SPY2 is an adaptive platform trial that features multiple arms of experimental agents administered on a background of standard neoadjuvant therapy with paclitaxel and adriamycin/cyclophosphamide, followed by definitive surgery. The adaptive randomization engine preferentially assigns patients based upon cumulative performance of each agent in a given breast cancer subtype based on hormone receptor and HER2 receptor status.
Vanishing bile duct syndrome: a sequela of temozolomide and levetiracetam-induced cholestatic liver injury.
BMJ Case Rep
November 2024
Essentia Health Fargo Hospital, Fargo, North Dakota, USA.
Temozolomide (TMZ)-levetiracetam (LEV) combination therapy in glioblastoma management is gradually becoming a mainstay treatment given its superior effect compared with TMZ monotherapy. While there have been previous cases of hepatotoxicity, there are no prior reports of vanishing bile duct syndrome (VBDS) associated with TMZ-LEV combination use. This case report details a male in his 50s who had recently completed TMZ and LEV for right frontal lobe glioblastoma.
View Article and Find Full Text PDFVanishing Bile Duct Syndrome in Pediatric Hodgkin Lymphoma: First Statistical Analysis of All Published Cases in Children and a Case Report.
J Pediatr Hematol Oncol
January 2025
Departments of Pediatric Hematology/Oncology and Bone Marrow Transplant.
Hodgkin lymphoma with vanishing bile duct syndrome is a rare paraneoplastic syndrome and has never been studied in the pediatric population. The objectives of this study were to determine the clinical characteristics of this rare condition in children through a literature review, and a descriptive analysis of all published cases with the index case report. All reported cases fulfilling the inclusion criteria were found through a literature search, and analyzed in descriptive statistics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!